Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Myeloid Leukemia (CML) Market Outlook

Thelansis’s “Chronic Myeloid Leukemia (CML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Myeloid Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Myeloid Leukemia (CML) Overview

Chronic myeloid leukemia (CML), a type of myeloproliferative disorder, represents a significant proportion of leukemia cases globally. Its hallmark is the presence of the Philadelphia chromosome, arising from a specific translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)), which generates an aberrant tyrosine kinase due to the BCR/ABL gene fusion. While CML isn't hereditary, the exact factors predisposing individuals to this condition remain unclear. CML typically progresses through three phases: chronic (CML-CP), accelerated (CML-AP), and blast (CML-BP). Diagnosis often occurs during the chronic phase, which might be asymptomatic or manifest with symptoms like fatigue, anemia, weight loss, night sweats, or an enlarged spleen. Treatment strategies for chronic myeloid leukemia vary based on disease stage. In the asymptomatic chronic phase, initial therapy usually involves tyrosine kinase inhibitors (such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib), demonstrating high efficacy, although not curative. These inhibitors may also be employed in the accelerated or blast phases. Allogeneic hematopoietic stem cell transplantation is typically reserved for patients with advanced CML or those resistant to tyrosine kinase inhibitors. The advent of tyrosine kinase inhibitors has markedly improved survival rates for chronic phase CML, exceeding 90% at the 5-year mark post-diagnosis. Before their availability, despite treatment, mortality rates were notably higher, with 5 to 10% succumbing within 2 years of diagnosis and an additional 10 to 15% annually after that, resulting in a median survival of 4 to 7 years. Most deaths, around 90%, occurred following progression to blast or accelerated phases, with a median survival of approximately 3 to 6 months in blast crisis unless remission was achieved.

• The annual incidence of CML ranges from 0.4 to 1.75 cases per 100,000 individuals globally.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: